Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 known ✓ | P00742 | 4/20 | 0.47 |
| ▸ | SERPINC1 known ✓ | P01008 | 2/20 | 0.42 |
| ▸ | FGF1 known ✓ | P05230 | 1/20 | 0.42 |
| ▸ | BMP2 | P12643 | 2/20 | 0.52 |
| ▸ | VEGFA | P15692 | 2/20 | 0.52 |
| ▸ | CXCL12 | P48061 | 2/20 | 0.52 |
| ▸ | SHH | Q15465 | 2/20 | 0.52 |
| ▸ | HPSE | Q9Y251 | 11/20 | 0.50 |
| ▸ | PF4 | P02776 | 2/20 | 0.48 |
| ▸ | IFNG | P01579 | 1/20 | 0.48 |
| ▸ | CCL2 | P13500 | 1/20 | 0.48 |
| ▸ | SELP | P16109 | 1/20 | 0.48 |
| ▸ | BMP6 | P22004 | 1/20 | 0.48 |
| ▸ | CCL11 | P51671 | 1/20 | 0.48 |
| ▸ | WNT3A | P56704 | 1/20 | 0.48 |
| ▸ | SELPLG | Q14242 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17167539 | 0.70 | BDNF (0.51) | BMP2VEGFACXCL12SHHHPSE | |
| SCHEMBL17167857 | 0.68 | F10 (0.53) | BMP2VEGFACXCL12SHHHPSE | |
| Fondaparinux SCHEMBL4937 | 0.63 | F10 (1.00) | BMP2VEGFACXCL12SHHHPSE | |
| SCHEMBL30013150 | 0.63 | CXCL12 (0.56) | BMP2VEGFACXCL12SHHHPSE | |
| SCHEMBL29772341 | 0.62 | LGALS8 (0.52) | HPSEFGF1 | |
| SCHEMBL17167553 | 0.61 | BDNF (0.55) | BMP2VEGFACXCL12SHHHPSE | |
| SCHEMBL17167551 | 0.60 | F10 (0.55) | CXCL12HPSECCL2F10SERPINC1 | |
| SCHEMBL17879093 | 0.60 | F10 (0.53) | BMP2VEGFACXCL12SHHHPSE | |
| Idraparinux SCHEMBL1652150 | 0.60 | SERPINC1 (1.00) | HPSEF10SERPINC1F2FGF1 | |
| SCHEMBL12360709 | 0.59 | F10 (0.62) | CXCL12HPSECCL2F10SERPINC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014177-A1 | ANTIHYPERTENSIVE DRUG AND ANTIHYPERTENSIVE FOOD COMPOSITION | MARUKYOU SUISAN CO., LTD. (JP) | 2026-01-15 | — | — | US | claimed |
| US-20250120999-A1 | SYSTEMS AND METHODS USING SULFATED GLYCOSAMINOGLYCANS (GAGs) AND GAG ANALOGS TO TREAT OR PREVENT MONKEYPOX (MPOX) | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2025-04-17 | — | — | US | claimed |
| US-20250025537-A1 | GLYCOSAMINOGLYCAN INHIBITOR AND PROMOTER | S&K BIOPHARMA, INC. (JP) | 2025-01-23 | — | — | US | claimed |
| US-20240309035-A1 | ENZYMATIC SYNTHESIS OF HOMOGENEOUS CHONDROITIN SULFATE OLIGOSACCHARIDES | UNIV NORTH CAROLINA CHAPEL HILL (US) | 2024-09-19 | — | — | US | claimed |
| US-20240180148-A1 | EFFICIENT BIOCOMPATIBLE CRYOPRESERVATION MEDIUM THAT ELIMINATES THE NEED FOR CELL PERMEATING CRYOPROTECTANTS | CRYOCRATE LLC (US) | 2024-06-06 | — | — | US | claimed |
| US-11993627-B2 | Enzymatic synthesis of homogeneous chondroitin sulfate oligosaccharides | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2024-05-28 | — | — | US | claimed |
| CN-117887803-A | Method for determining inhibition of hyaluronidase activity by mucopolysaccharide polysulfonate | 重庆望业药物研究有限公司 | 2024-04-16 | — | — | CN | claimed |
| WO-2024044398-A1 | SYSTEMS AND METHODS USING SULFATED GLYCOSAMINOGLYCANS (GAGS) AND GAG ANALOGS TO TREAT OR PREVENT MONKEYPOX (MPOX) | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2024-02-29 | — | — | WO | claimed |
| EP-4319554-A1 | EFFICIENT BIOCOMPATIBLE CRYOPRESERVATION MEDIUM THAT ELIMINATES THE NEED FOR CELL PERMEATING CRYOPROTECTANTS | CryoCrate LLC (US) | 2024-02-14 | — | — | EP | claimed |
| CN-117177663-A | Efficient biocompatible cryopreservation media eliminating the need for cell permeable cryoprotectants | 库瑞欧库瑞特有限公司 | 2023-12-05 | — | — | CN | claimed |
| CN-116969800-A | Organic fertilizer for soil remediation and preparation method thereof | 广州致高环保新材料科技有限公司 | 2023-10-31 | — | — | CN | claimed |
| WO-2022216676-A1 | EFFICIENT BIOCOMPATIBLE CRYOPRESERVATION MEDIUM THAT ELIMINATES THE NEED FOR CELL PERMEATING CRYOPROTECTANTS | CRYOCRATE LLC (US) | 2022-10-13 | — | — | WO | claimed |
| CN-122031445-A | External pharmaceutical composition containing loxoprofen | 第一三共健康事业株式会社 | 2026-05-15 | — | — | CN | disclosed |
| US-12624128-B2 | Low molecular weight chondroitin sulfate, composition, preparation method and use thereof | Nanjing Hanxin Pharmaceutical Technology Co., Ltd. (CN) | 2026-05-12 | — | — | US | disclosed |
| US-20260124237-A1 | CARTILAGE REGENERATION COMPOSITION | KOBAYASHI PHARMACEUTICAL CO LTD (JP) | 2026-05-07 | — | — | US | disclosed |
| US-20260014177-A1 | ANTIHYPERTENSIVE DRUG AND ANTIHYPERTENSIVE FOOD COMPOSITION | MARUKYOU SUISAN CO., LTD. (JP) | 2026-01-15 | — | — | US | disclosed |
| US-20220142948-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC REGULATORS OF T CELL PATHOGENICITY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2022-05-12 | — | — | US | disclosed |
| CN-114317640-A | Method for preparing chondroitin sulfate with different molecular weights based on PAPS | 江南大学 | 2022-04-12 | — | — | CN | disclosed |
| EP-3969014-A1 | METHOD FOR MODULATING ENDOTHELIAL GLYCOCALYX STRUCTURE | ExThera Medical Corporation (US) | 2022-03-23 | — | — | EP | disclosed |
| US-20220046941-A1 | SILICA MICROCAPSULES AND METHODS OF PREPARING SAME | INTERNATIONAL FLAVORS & FRAGRANCES INC. | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11993627-B2 | Enzymatic synthesis of homogeneous chondroitin sulfate oligosaccharides | HPSE, STS, CSGALNACT1 | F10 3602/4885SERPINC1 995/4885FGF1 2990/4885 |
| US-20240309035-A1 | ENZYMATIC SYNTHESIS OF HOMOGENEOUS CHONDROITIN SULFATE OLIGOSACCHARIDES | HPSE, STS, CSGALNACT1 | F10 3602/4885SERPINC1 995/4885FGF1 2990/4885 |
| US-12624128-B2 | Low molecular weight chondroitin sulfate, composition, preparation method and use thereof | COL2A1, CD44, COL1A1 | F10 407/4885SERPINC1 216/4885FGF1 440/4885 |
| US-20260124237-A1 | CARTILAGE REGENERATION COMPOSITION | CSGALNACT1, CD44, HCAR1 | F10 2283/4885SERPINC1 132/4885FGF1 156/4885 |
| US-20260014177-A1 | ANTIHYPERTENSIVE DRUG AND ANTIHYPERTENSIVE FOOD COMPOSITION | CSGALNACT1, MMP7, CHIA | F10 1516/4885SERPINC1 101/4885FGF1 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.